Analysts' ratings for Halozyme Therapeutics HALO over the last quarter vary from bullish to bearish, as provided by 7 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $75.57, with a high estimate of $91.00 and a low estimate of $60.00. This current average reflects an increase of 10.21% from the previous average price target of $68.57.
Decoding Analyst Ratings: A Detailed Look
The standing of Halozyme Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell S. Kapoor | HC Wainwright & Co. | Raises | Buy | $85.00 | $75.00 |
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $80.00 | $75.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $63.00 | $60.00 |
| Jason N. Butler | JMP Securities | Raises | Market Outperform | $91.00 | $78.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Raises | Buy | $75.00 | $72.00 |
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $75.00 | $62.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $60.00 | $58.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Halozyme Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halozyme Therapeutics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Halozyme Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Halozyme Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Halozyme Therapeutics analyst ratings.
Discovering Halozyme Therapeutics: A Closer Look
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Breaking Down Halozyme Therapeutics's Financial Performance
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Halozyme Therapeutics's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 40.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Halozyme Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 50.71%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Halozyme Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 40.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Halozyme Therapeutics's ROA excels beyond industry benchmarks, reaching 7.77%. This signifies efficient management of assets and strong financial health.
Debt Management: Halozyme Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 4.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
